TY - JOUR
T1 - Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial
AU - Solidarity Finland Investigators
AU - Nevalainen, Olli P.O.
AU - Horstia, Saana
AU - Laakkonen, Sanna
AU - Rutanen, Jarno
AU - Mustonen, Jussi M.J.
AU - Kalliala, Ilkka E.J.
AU - Ansakorpi, Hanna
AU - Kreivi, Hanna Riikka
AU - Kuutti, Pauliina
AU - Paajanen, Juuso
AU - Parkkila, Seppo
AU - Paukkeri, Erja Leena
AU - Perola, Markus
AU - Pourjamal, Negar
AU - Renner, Andreas
AU - Rosberg, Tuomas
AU - Rutanen, Taija
AU - Savolainen, Joni
AU - Haukka, Jari K.
AU - Guyatt, Gordon H.
AU - Tikkinen, Kari A.O.
N1 - Funding Information:
The authors would like to thank the participating patients, their families, and the hospital staff. The Academy of Finland (335527; K.A.O.T.), Foundation of the Finnish Anti-Tuberculosis Association (K.A.O.T.), Helsinki University Hospital (TYH2022330; K.A.O.T.), Päivikki and Sakari Sohlberg Foundation (K.A.O.T.), Sigrid Jusélius Foundation (K.A.O.T.), Tampere Tuberculosis Foundation (J.R. and K.A.O.T.), and Tampere University Hospital State Research Funding (9AC085; J.R.) funded this study. World Health Organization (WHO) provided the study drug (remdesivir), donated by Gilead Sciences. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Funding Information:
The authors would like to thank the participating patients, their families, and the hospital staff. The Academy of Finland (335527; K.A.O.T.), Foundation of the Finnish Anti-Tuberculosis Association (K.A.O.T.), Helsinki University Hospital (TYH2022330; K.A.O.T.), Päivikki and Sakari Sohlberg Foundation (K.A.O.T.), Sigrid Jusélius Foundation (K.A.O.T.), Tampere Tuberculosis Foundation (J.R. and K.A.O.T.), and Tampere University Hospital State Research Funding (9AC085; J.R.) funded this study. World Health Organization (WHO) provided the study drug (remdesivir), donated by Gilead Sciences. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/10
Y1 - 2022/10
N2 - We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.
AB - We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.
U2 - 10.1038/s41467-022-33825-5
DO - 10.1038/s41467-022-33825-5
M3 - Article
C2 - 36257950
AN - SCOPUS:85140079584
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
M1 - 6152
ER -